NASDAQ · BMRN
BioMarin Pharmaceutical Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BMRN: Nov 02, 2026
BioMarin Pharmaceutical Inc. Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.30 | $0.01 | $-0.48 | 6 |
| Dec 2026 | $1.40 | $1.55 | $1.12 | 7 |
| Mar 2027 | $1.24 | $1.32 | $1.05 | 4 |
| Jun 2027 | $1.36 | $1.58 | $0.99 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat- RTTNews · Oct 29, 2:41 PM EDTBioMarin Inks $475M License Deal For Investigational Fabry Disease Therapy(RTTNews) – BioMarin Pharmaceutical Inc. (BMRN) announced an exclusive worldwide licensing agreement with GC Biopharma Corp (006280.KS) and Hanmi Pharm Co., Ltd (128940.KS). to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy fo
- Zacks · Oct 22, 9:00 AM EDTEarnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to DeclineBristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 19, 9:00 AM EDTBioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 13, 8:40 AM EDTHere's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- Zacks · Oct 7, 10:37 AM EDTFDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingBBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
- RTTNews · Oct 2, 11:43 AM EDTBioMarin Adds Five-Year Evidence For POMBILITI + OPFOLDA; Stock Down(RTTNews) – Friday, BioMarin Pharmaceutical Inc. (BMRN) reported five-year Phase 3 data for POMBILITI (cipaglucosidase alfa-atga) in combination with OPFOLDA (miglustat) in adults with late-onset Pompe disease (LOPD), while the company's shares traded lower.
- RTTNews · Oct 2, 11:32 AM EDTBioMarin Reports 5-Year Motor, Lung Data For Pompe Disease Therapy(RTTNews) – On Friday, BioMarin Pharmaceutical (BMRN) reported five-year Phase 3 data for POMBILITI + OPFOLDA in adults with late-onset Pompe disease (LOPD) at the World Muscle Society Congress in Hiroshima, Japan.
- MarketBeat · Sep 18, 1:02 PM EDTBioMarin Targets Amicus Synergies as VOXZOGO Nears $1B MilestoneCan BioMarin Stock Live Up to Wall Street’s High Expectations?BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acqui
- Zacks · Sep 18, 1:00 PM EDTFDA Grants Priority Review to AZN's Filing for Rare Bone Disease DrugAstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
- Zacks · Sep 16, 12:01 PM EDTBioMarin Stops Voxzogo Development for Noonan SyndromeBMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 9, 11:30 AM EDTBioMarin's VOXZOGO Hits Phase 3 Growth Endpoint In Hypochondroplasia(RTTNews) – BioMarin Pharmaceutical Inc. (BMRN) announced that its Phase 3 CANOPY-HCH-3 study of VOXZOGO (vosoritide) in children with hypochondroplasia met its primary endpoint, showing statistically significant improvements in annualized growth velocity compared to placebo.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for BioMarin Pharmaceutical Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.